Pierre Geborek
101 – 120 of 135
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2005
-
Mark
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
(
- Contribution to journal › Article
-
Mark
Response criteria for rheumatoid arthritis in clinical practice - how useful are they?
(
- Contribution to journal › Article
-
Mark
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
(
- Contribution to journal › Article
-
Mark
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
(
- Contribution to journal › Article
-
Mark
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas
(
- Contribution to journal › Article
-
Mark
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis
(
- Contribution to journal › Article
- 2004
-
Mark
Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al
(
- Contribution to journal › Letter
-
Mark
TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
(
- Contribution to journal › Scientific review
- 2003
-
Mark
Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept.
(
- Contribution to journal › Article
- 2002
-
Mark
Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.
(
- Contribution to journal › Article
-
Mark
Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage.
(
- Contribution to journal › Article
- 2001
-
Mark
Release of cartilage and bone macromolecules into synovial fluid: differences between psoriatic arthritis and rheumatoid arthritis
(
- Contribution to journal › Article
-
Mark
Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma)
(
- Contribution to journal › Article
- 2000
-
Mark
Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis
(
- Contribution to journal › Article
- 1997
-
Mark
Cartilage and bone macromolecules in knee joint synovial fluid in rheumatoid arthritis: relation to development of knee or hip joint destruction
(
- Contribution to journal › Article
- 1995
-
Mark
Hip involvement in early rheumatoid arthritis
(
- Contribution to journal › Article
- 1994
-
Mark
Prevention of joint destruction in antigen-induced arthritis
(
- Contribution to journal › Article
- 1993
-
Mark
Antiproliferative effects on human peripheral blood mononuclear cells and inhibition of in vitro immunoglobulin synthesis by Podophyllotoxin (CPH86) and by semisynthetic lignan glycosides (CPH82)
(
- Contribution to journal › Article
-
Mark
Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis
(
- Contribution to journal › Article
- 1992
-
Mark
Cytidine deaminase and lactoferrin in inflammatory synovial fluids. Indicators of local polymorphonuclear cell function?
(
- Contribution to journal › Article